ReviewJournal of the National Medical Association
Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.
Review in Journal of the National Medical Association. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Management of opioid use disorders: a national clinical practice guideline.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2018Guideline
- Effects of Buprenorphine/Naloxone and Methadone on Depressive Symptoms in People with Prescription Opioid Use Disorder: A Pragmatic Randomised Controlled Trial.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2023Trial
- Effects of access barriers and medication acceptability on buprenorphine-naloxone treatment utilization over 2 years: Results from a multisite randomized trial of adults with opioid use disorder.Journal of substance abuse treatment · 2019Trial
- Memory function in patients with opioid dependence treated with buprenorphine and methadone in comparison with healthy persons.Scientific reports · 2025Article
- A National Portrait of Public Attitudes toward Opioid Use in the US: A Latent Class Analysis.International journal of environmental research and public health · 2023Article
- The four-factor personality model and its qualitative correlates among opioid agonist therapy clients.Frontiers in psychiatry · 2023Article
- A bifurcated opioid treatment system and widening insidious disparities.Addictive behaviors · 2022Article
- Mitragynine improves cognitive performance in morphine-withdrawn rats.Psychopharmacology · 2022Article
- Factors That Affect Patient Attrition in Buprenorphine Treatment for Opioid Use Disorder: A Retrospective Real-World Study Using Electronic Health Records.Neuropsychiatric disease and treatment · 2021Article
- Untangling the Complexities of Substance Use Initiation and Recovery: Client Reflections on Opioid Use Prevention and Recovery From a Social-Ecological Perspective.Substance abuse : research and treatment · 2021Article
- Pharmacokinetic Characterization and External Evaluation of a Quantitative Framework of Sublingual Buprenorphine in Patients with an Opioid Disorder in Puerto Rico.Pharmaceutics · 2020Article
- Nicotine and Opioids: a Call for Co-treatment as the Standard of Care.The journal of behavioral health services & research · 2020Review
- Understanding concurrent stimulant use among people on methadone: A qualitative study.Drug and alcohol review · 2020Article
- "It's Took Over This Region": Patient Perspectives of Prescription Drug Abuse in Appalachia.Substance use & misuse · 2020Article
- Investigation of Novel Primary and Secondary Pharmacophores and 3-Substitution in the Linking Chain of a Series of Highly Selective and Bitopic Dopamine DJournal of medicinal chemistry · 2019Article
- Discovering major opioid-related research themes over time: A text mining technique.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2019Article
- Racial Bias in the US Opioid Epidemic: A Review of the History of Systemic Bias and Implications for Care.Cureus · 2018Review
- Drug addiction: a curable mental disorder?Acta pharmacologica Sinica · 2018Review
- Targeting multiple opioid receptors - improved analgesics with reduced side effects?British journal of pharmacology · 2018Review
- Optimising treatment in opioid dependency in primary care: results from a national key stakeholder and expert focus group in Ireland.BMC family practice · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Opioid abuse and addiction have increased in frequency in the United States over the past 20 years. In 2009, an estimated 5.3 million persons used opioid medications nonmedically within the past month, 200000 used heroin, and approximately 9.6% of African Americans used an illicit drug. Racial and ethnic minorities experience disparities in availability and access to mental health care, including substance use disorders. Primary care practitioners are often called upon to differentiate between appropriate, medically indicated opioid use in pain management vs inappropriate abuse or addiction. Racial and ethnic minority populations tend to favor primary care treatment settings over specialty mental health settings. Recent therapeutic advances allow patients requiring specialized treatment for opioid abuse and addiction to be managed in primary care settings. The Drug Addiction Treatment Act of 2000 enables qualified physicians with readily available short-term training to treat opioid-dependent patients with buprenorphine in an office-based setting, potentially making primary care physicians active partners in the diagnosis and treatment of opioid use disorders. Methadone and buprenorphine are effective opioid replacement agents for maintenance and/or detoxification of opioid-addicted individuals. However, restrictive federal regulations and stigmatization of opioid addiction and treatment have limited the availability of methadone. The opioid partial agonist-antagonist buprenorphine/naloxone combination has proven an effective alternative. This article reviews the literature on differences between buprenorphine and methadone regarding availability, efficacy, safety, side-effects, and dosing, identifying resources for enhancing the effectiveness of medication-assisted recovery through coordination with behavioral/psychological counseling, embedded in the context of recovery-oriented systems of care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.